Development of new imidazopyridine-based chalcones hybrids as potent antidiabetic and antioxidant agents: synthesis, in silico and in vitro evaluation
Hanan Abdelmawgoud Atia, Aladdin M. Srour, Hanaa Farag, Wael Mahmoud Aboulthana, Abdulrahman M. Saleh, Mohamed Gamal Thabit, Ranza Elrayess, Asmaa Saleh, Jarosław Dziadek, Ahmed Sabt · 2026
Read Development of new imidazopyridine-based chalcones hybrids as potent antidiabetic and antioxidant agents: synthesis, in silico and in vitro evaluation by Hanan Abdelmawgoud Atia, Aladdin M. Srour, Hanaa Farag, Wael Mahmoud Aboulthana, Abdulrahman M. Saleh, Mohamed Gamal Thabit, Ranza Elrayess, Asmaa Saleh, Jarosław Dziadek, Ahmed Sabt (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13529672.txt.
Description
Hanan Atia and nine co-authors fuse two drug scaffolds into six new molecules and screen them against diabetes enzymes and free radicals. The hybrids join an imidazopyridine core to chalcone arms. In glass assays every compound showed some antioxidant and enzyme-blocking power, and two stood out. Compound 5f led the antioxidant tests at levels rivaling ascorbic acid, and it blocked the three target enzymes hardest.
Docking put 5f snug in aldose reductase, tighter than a reference drug, while 5c favored the two starch enzymes. A hundred-nanosecond simulation kept the champion complex stable. The series offers leads for dual-action diabetes drugs.
Catalog record
| CREATOR | Hanan Abdelmawgoud Atia, Aladdin M. Srour, Hanaa Farag, Wael Mahmoud Aboulthana, Abdulrahman M. Saleh, Mohamed Gamal Thabit, Ranza Elrayess, Asmaa Saleh, Jarosław Dziadek, Ahmed Sabt |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |